menu
    • menu

    Company profile for YolTech Therapeutics

    NEW Drugs in Dev: 5
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    YolTech Therapeutics, a biotech company, specializes in integrating mRNA and gene editing technology to advance next-generation mRNA drugs and in vivo gene editing drugs. As a pre-clinical stage gene editing biotech, YolTech has established a leading genome editing platform and mRNA-LNP library, showcasing proficiency in the discovery of novel Cas and base editors. With robust production capabilities for LNP drug manufacturing...
    YolTech Therapeutics, a biotech company, specializes in integrating mRNA and gene editing technology to advance next-generation mRNA drugs and in vivo gene editing drugs. As a pre-clinical stage gene editing biotech, YolTech has established a leading genome editing platform and mRNA-LNP library, showcasing proficiency in the discovery of novel Cas and base editors. With robust production capabilities for LNP drug manufacturing and global IP protection, the company has developed a pipeline featuring 10 genetic medicines concentrated on cardiovascular diseases, infectious diseases, and rare diseases.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    YolTech TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    No. 58 Tanzhu Road, Minhang District, Shanghai
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.yoltx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/yoltech-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Clinical Outsourcing

    Clinical Outsourcing

    Not Confirmed

    envelop Contact Supplier

    Clinical Outsourcing

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Yoltech Therapeutics Reports Positive Interim Data For YOLT-202
    Yoltech Therapeutics Reports Positive Interim Data For YOLT-202

    19 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-19/yoltech-therapeutics-announces-positive-interim-data-on-yolt-202-for-the-treatment-of-alpha-1-antitr

    PHARMIWEB
    19 Feb 2026
    Share Share
    YolTech Secures $45M in AstraZeneca-CICC Led Series B Funding
    YolTech Secures $45M in AstraZeneca-CICC Led Series B Funding

    11 Sep 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/yoltech-therapeutics-raises-45-million-in-series-b-financing-led-by-astrazeneca-cicc-302553734.html

    PR NEWSWIRE
    11 Sep 2025
    Share Share
    YolTech Therapeutics: FDA Clears YOLT-101 IND for HeFH Treatment
    YolTech Therapeutics: FDA Clears YOLT-101 IND for HeFH Treatment

    05 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-yolt-101-an-in-vivo-base-editing-therapy-to-treat-heterozygous-familial-hypercholesterolemia-hefh-302475072.html

    PR NEWSWIRE
    05 Jun 2025
    Share Share
    YolTech Releases Data on YOLT-101 Trial for Hypercholesterolemia
    YolTech Releases Data on YOLT-101 Trial for Hypercholesterolemia

    28 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/yoltech-announces-first-clinical-data-from-ongoing-investigator-initiated-trial-of-yolt-101-an-in-vivo-base-editing-therapy-for-familial-hypercholesterolemia-302439382.html

    PR NEWSWIRE
    28 Apr 2025
    Share Share
    YolTech Therapeutics: Positive Data of YOLT-203 for PH1
    YolTech Therapeutics: Positive Data of YOLT-203 for PH1

    25 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/yoltech-therapeutics-announces-positive-clinical-data-for-yolt-203-an-in-vivo-gene-editing-therapy-for-primary-hyperoxaluria-type-1-ph1-302384408.html

    PR NEWSWIRE
    25 Feb 2025
    Share Share
    YolTech To Start Trial For Gene Therapy YOLT-204 In β-Thalassemia
    YolTech To Start Trial For Gene Therapy YOLT-204 In β-Thalassemia

    22 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/yoltech-therapeutics-to-initiate-a-clinical-trial-for-yolt-204-a-first-in-class-bone-marrow-targeted-in-vivo-gene-editing-therapy-for--thalassemia-302355739.html

    PR NEWSWIRE
    22 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search